Breakdown | |||||
TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
855.01B | 851.49B | 858.25B | 798.68B | 679.74B | 679.50B | Gross Profit |
188.86B | 190.18B | 184.13B | 160.62B | 148.08B | 189.09B | EBIT |
45.37B | 46.38B | 47.79B | 32.83B | 29.43B | 27.20B | EBITDA |
74.14B | 82.05B | 76.91B | 59.55B | 58.35B | 54.91B | Net Income Common Stockholders |
32.76B | 34.69B | 31.74B | -10.38B | 17.51B | 19.01B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
114.29B | 96.12B | 109.47B | 82.97B | 70.71B | 61.73B | Total Assets |
829.63B | 789.71B | 826.70B | 713.87B | 723.07B | 687.41B | Total Debt |
81.47B | 84.53B | 88.31B | 85.05B | 79.51B | 76.95B | Net Debt |
-27.23B | -9.44B | -19.37B | 2.07B | 9.91B | 15.67B | Total Liabilities |
301.46B | 287.14B | 310.32B | 275.38B | 262.43B | 242.64B | Stockholders Equity |
510.37B | 485.01B | 500.30B | 423.88B | 449.27B | 433.20B |
Cash Flow | Free Cash Flow | ||||
11.83B | 13.74B | 44.00B | 4.76B | 23.15B | 32.15B | Operating Cash Flow |
19.71B | 55.21B | 73.19B | 23.42B | 41.83B | 49.51B | Investing Cash Flow |
-8.56B | -34.96B | -30.94B | 487.00M | -15.52B | -17.11B | Financing Cash Flow |
-2.29B | -35.43B | -19.54B | -10.63B | -17.85B | -31.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $8.92B | 15.03 | 4.68% | 6.11% | 3.59% | -2.49% | |
60 Neutral | ¥487.53B | 14.65 | 3.49% | -0.79% | 9.92% | ||
$2.44B | 17.01 | 10.34% | 1.98% | ― | ― | ||
$6.04B | 16.99 | 11.20% | 2.18% | ― | ― | ||
$1.15B | 7.43 | 10.43% | 2.83% | ― | ― | ||
$4.49B | 17.25 | 8.78% | 1.45% | ― | ― | ||
€921.44M | 12.47 | 6.86% | 3.68% | ― | ― |
Nisshin Seifun Group Inc. is restructuring its business portfolio to align with its Medium-Term Management Plan 2026, aiming for sustainable growth. As part of this restructuring, Nisshin Pharma will cease its fine chemicals business and transfer its healthcare foods business to Oriental Yeast Co., Ltd., which is expected to enhance the healthcare foods segment. This move is driven by a challenging business environment for Nisshin Pharma’s fine chemicals and aims to leverage Oriental Yeast’s capabilities in food materials. The restructuring will result in an extraordinary loss of 2,276 million yen, impacting the company’s financial results.
Nisshin Seifun Group Inc. reported a slight decrease in net sales and operating profit for the fiscal year ending March 31, 2025, compared to the previous year. Despite this, the company increased its dividends per share, indicating a commitment to shareholder returns. The forecast for the next fiscal year shows a modest growth in net sales and profits, suggesting a positive outlook for the company’s financial performance.
Nisshin Seifun Group Inc. announced a change in its executive leadership, with Kenji Sakamoto appointed as the new Representative Director and Senior Managing Executive Officer, replacing Naoto Masujima, who will become a Senior Corporate Adviser. This leadership transition is part of the company’s strategic restructuring to enhance its executive framework, potentially impacting its operational efficiency and industry positioning.